<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01528514</url>
  </required_header>
  <id_info>
    <org_study_id>MRG5380258</org_study_id>
    <nct_id>NCT01528514</nct_id>
  </id_info>
  <brief_title>Effects of CUrcuminoids on Coronary Artery byPass graftIng-related myocarDial Infarction Study</brief_title>
  <acronym>CUPID</acronym>
  <official_title>The Effects of CUrcuminoids on Coronary Artery byPass graftIng-related myocarDial Infarction Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wanwarang Wongcharoen, MD.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Thailand Research Fund</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is well-established that myocardial infarction (MI) associated with coronary artery bypass
      graft surgery (CABG) predicts the poor outcome. Nevertheless, the cardioprotective therapies
      to limit myocardial injury after CABG are lacking. Previous studies have shown that
      curcuminoids suppress pro-inflammatory cytokines during cardiopulmonary bypass surgery and
      decrease the occurrence of cardiomyocytic apoptosis after cardiac ischemia/reperfusion injury
      in animal models. The investigators aim to evaluate whether curcuminoids prevent MI after
      CABG, compared to placebo.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2009</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of postoperative myocardial infarction</measure>
    <time_frame>participants will be followed for the duration of hospital stay, an expected average of 10 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Coronary Artery Bypass Grafting</condition>
  <arm_group>
    <arm_group_label>Curcuminoids</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Curcuminoids</intervention_name>
    <description>Curcuminoids in capsule form, 4 capsules four times daily (4 grams/day)</description>
    <arm_group_label>Curcuminoids</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo in capsule form, 4 capsules 4 times/day</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients undergoing CABG without valve surgery

        Exclusion Criteria:

          -  emergency cardiac surgery

          -  any increase in CK-MB above upper limit of normal range (ULN) at the time of
             randomization

          -  patients with cholestatic jaundice (total bilirubin &gt; 2-fold ULN)

          -  severe liver disease (AST or ALT &gt; 3-fold ULN)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wanwarang Wongcharoen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculty of Medicine, Chiang Mai university</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wanwarang Wongcharoen, MD</last_name>
    <phone>+66 53 946713</phone>
    <email>bwanwarang@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Maharaj Nakorn Chiang Mai hospital</name>
      <address>
        <city>Muang</city>
        <state>Chiang Mai</state>
        <zip>50210</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wanwarang Wongcharoen, MD</last_name>
      <phone>+66 53 946713</phone>
      <email>bwanwarang@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Wanwarang Wongcharoen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 31, 2012</study_first_submitted>
  <study_first_submitted_qc>February 7, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2012</study_first_posted>
  <last_update_submitted>February 7, 2012</last_update_submitted>
  <last_update_submitted_qc>February 7, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 8, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Thailand Research Fund</investigator_affiliation>
    <investigator_full_name>Wanwarang Wongcharoen, MD.</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>Myocardial infarction</keyword>
  <keyword>Coronary artery bypass grafting</keyword>
  <keyword>Anti-oxidant</keyword>
  <keyword>Curcuminoids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

